NR4A1 and breast carcinoma: Compared with tamoxifen, they can significantly reduce the absolute risk of recurrence after 10 years and improve the overall survival rate.[2] American Society of Clinical Oncology clinical practice guidelines recommended that the treatment of AIs in postmenopausal women with hormone receptor-positive breast cancer was extended to 10 years, especially those with node-positive patients.[3] Despite its benefits in breast cancer treatment, its musculoskeletal impact cannot be ignored.